These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28723151)

  • 1. Fusion of Structure and Ligand Based Methods for Identification of Novel CDK2 Inhibitors.
    Mahajan P; Chashoo G; Gupta M; Kumar A; Singh PP; Nargotra A
    J Chem Inf Model; 2017 Aug; 57(8):1957-1969. PubMed ID: 28723151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
    Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches.
    Li HL; Ma Y; Ma Y; Li Y; Chen XB; Dong WL; Wang RL
    Oncotarget; 2017 May; 8(20):33225-33240. PubMed ID: 28402259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New scoring functions for virtual screening from molecular dynamics simulations with a quantum-refined force-field (QRFF-MD). Application to cyclin-dependent kinase 2.
    Ferrara P; Curioni A; Vangrevelinghe E; Meyer T; Mordasini T; Andreoni W; Acklin P; Jacoby E
    J Chem Inf Model; 2006; 46(1):254-63. PubMed ID: 16426061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA.
    Mascarenhas NM; Ghoshal N
    Eur J Med Chem; 2008 Dec; 43(12):2807-18. PubMed ID: 18037537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.
    Duca JS
    Future Med Chem; 2009 Nov; 1(8):1453-66. PubMed ID: 21426059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
    Kontopidis G; McInnes C; Pandalaneni SR; McNae I; Gibson D; Mezna M; Thomas M; Wood G; Wang S; Walkinshaw MD; Fischer PM
    Chem Biol; 2006 Feb; 13(2):201-11. PubMed ID: 16492568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the mechanism of action of spirooxindoles as a class of CDK2 inhibitors: a structure-based computational approach.
    Abdjan MI; Shafiq M; Nerukh D; Nur-E-Alam M; Ul-Haq Z
    Phys Chem Chem Phys; 2024 Jun; 26(22):16139-16152. PubMed ID: 38787638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents.
    Chohan TA; Qian H; Pan Y; Chen JZ
    Curr Med Chem; 2015; 22(2):237-63. PubMed ID: 25386824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors.
    Oudah KH; Najm MAA; Samir N; Serya RAT; Abouzid KAM
    Bioorg Chem; 2019 Nov; 92():103239. PubMed ID: 31513938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accurate Prediction of Complex Structure and Affinity for a Flexible Protein Receptor and Its Inhibitor.
    Bekker GJ; Kamiya N; Araki M; Fukuda I; Okuno Y; Nakamura H
    J Chem Theory Comput; 2017 Jun; 13(6):2389-2399. PubMed ID: 28482660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel CDK2 inhibitors by a multistage virtual screening method based on SVM, pharmacophore and docking model.
    Liang JW; Wang MY; Wang S; Li SL; Li WQ; Meng FH
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):235-244. PubMed ID: 31760818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
    Tripathi SK; Muttineni R; Singh SK
    J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of new small-molecule cyclin-dependent kinase 6 inhibitors through computational approaches.
    Luo X; Zhao Y; Tang P; Du X; Li F; Wang Q; Li R; He J
    Mol Divers; 2021 Feb; 25(1):367-382. PubMed ID: 32770459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics, density functional, ADMET predictions, virtual screening, and molecular interaction field studies for identification and evaluation of novel potential CDK2 inhibitors in cancer therapy.
    da Silva VB; Kawano DF; Gomes Ada S; Carvalho I; Taft CA; da Silva CH
    J Phys Chem A; 2008 Sep; 112(38):8902-10. PubMed ID: 18698751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cyclin-dependent kinase 2 CDK2: Insights from molecular docking and dynamics simulation - A systematic computational approach to discover novel cancer therapeutics.
    Chagaleti BK; B SK; G V A; Rajagopal R; Alfarhan A; Arockiaraj J; Muthu Kumaradoss K; Karthick Raja Namasivayam S
    Comput Biol Chem; 2024 Oct; 112():108134. PubMed ID: 38964206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.